Variation of chromogranin a serum levels after radical retropubic prostatectomy for prostate adenocarcinoma

Archives of Andrology

Volumn 49, Issue 1, 2003, Pages 39-48

  Sciarra, A ^a   Gentile, V ^a   Monti, S ^a   Mariotti, G ^a   Pastore, A ^a   Di Silverio, Franco ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Chromogranin A; Prostate neoplasm; Prostate specific antigen; Radical prostatectomy

Indexed keywords

CHROMOGRANIN A; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; PROTEIN ANALYSIS; SCORING SYSTEM; SURGICAL STRESS;

EID: 79961180159     PISSN: 01485016     EISSN: None     Source Type: Journal    
DOI: 10.1080/01485010390129160     Document Type: Article

References (23)

1. Abrahamsson PA (1999): Neuroendocrine differentiation in prostatic carcinoma. Prostate 39:135-148.
2. Ahlgren G, Pedersen K, Lundberg S, Aus G, Hugosson J, Abrahemsson PA (2000): Regressive changes and neuroendocrine differentiation in prostate cancer after neoadjuvant hormonal treatment. Prostate 42:274-279.
3. Berruti A, Dogliotti L, Mosca A (2000): Circulating neuroendocrine markers in patients with prostate carcinoma. Cancer 88:2590-2596.
4. Bjork T, Ljungberg B, Piironen T, Abrahamsson P, Pettersson K, Cockett ATK (1998): Rapid exponential elimination of free prostate specific antigen contrasts the slow capacity-limited elimination of PSA complexed to alpha-1-antichymotrypsin from serum. Urology 51:57-62.
5. Bonkhoff H (1998): Neuroendocrine cells in benign and malignant prostate tissue: Morphogenesis, proliferation and androgen receptor status. Prostate (suppl) 8:18-22.
6. Brandle E, Hautmann O, Bachem M (1999): Serum half-life time determination of free and total prostate specific antigen following radical prostatectomy: A critical assessment. Urology 53:722-730.
7. Casella R, Budendorf L, Sauter G, Moch H, Mihatsch MJ, Gasser TC (1998): Focal neuroendocrine differentiation lacks prognostic significance in prostate core needle biopsies. J Urol 160:406-410.
8. Cohen RJ (1991): Neuroendocrine cells: A new prognostic parameter in prostate cancer. Br J Urol 68:258-262.
9. Di Sant'Agnese PA (1992): Neuroendocrine differentiation in carcinoma of the prostate. Cancer 70:254-268.
10. Helpap B, Kollermann J, Oehler U (1999): Neuroendocrine differentiation in prostatic carcinomas: Histogenesis, biology, clinical relevance and future therapeutic perspectives. Urol Int 62:133-138.
11. Kanno T, Asada N, Yanase H, Iwanaga T, Ozaki T (1999): Salivary secretion of highly concentrated chromogranin A in response to noradrenaline and acetylcholine in isolated and perfused rat submandibular glands. Exp Physiol 84:1073-1083.
12. Krijnen J, Jansen P, Ruizeveld de Winter JA, van Kimpen H, Schroeder F, van der Kwast T (1993): Do neuroendocrine cells in human prostate cancer express androgen receptors? Histochemistry 100:393-398.
13. Krupski T, Petroni GR, Frierson HF (2000): Microvessel density, p53, retinoblastoma and chromogranin A immunohistochemistry as predictors of disease-specific survival following radical prostatectomy for carcinoma of the prostate. Urology 55:743-749.
14. Jiang Q, Taupenot L, Mahata SK, Mahata M, O'Connor DT (2001): Proteolytic cleavage of chromogranin A by plasmin: Selective liberation of a specific bioactive CgA fragment that regulates catecholamine release. J Biol Chem 276:25022-25029.
15. Lilja H, Haese A, Bjork T, Friedrich MG, Piironen T (1999): Significance and metabolism of complexed and noncomplexed prostate specific antigen forms, and human glandular kallikrein 2 in clinically localized prostate cancer before and after radical prostatectomy. J Urol 162:2029-2035.
16. Moftaquir-Handaj A, Barbe F, Barbarino-Monnier P (1995): Circulating chromogranin A and catecholamines in human fetuses at uneventful birth. Pediatr Res 37:101-105.
17. Monti S, Sciarra A, Falasca P, Di Silverio F (2000): Serum concentrations and prostatic gene expression of chromogranin A and PSA in patients affected by prostate cancer and benign prostatic hyperplasia. J Endocrin Invest 23 (suppl 8):53.
18. O'Connor DT, Bernstein KN (1984): Radioimmunoassay of chromogranin A in plasma as a measure of exocytotic sympathoadrenal activity in normal subjects and patients with pheochromocytoma. N Engl J Med 311:764-770.
19. Oesterling JE, Chan DW, Epstein JI, Kimball AW, Bruzel DJ, Walsh PC (1998): Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol 139:766-772.
20. Partin AW, Piantadosi S, Subong ENP, Kelly CA, Hortopan S, Chan DW (1996): Clearance rate of serum free and total PSA following radical retropubic prostatectomy. Prostate (suppl) 7:35-39.
21. Sanchez-Margalet V, Goberna R (1993): Pancreastatin decreases plasma epinephrine levels in surgical stress in the rat. Peptides 14:797-799.
22. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS (1987): Prostate specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317:909-916.
23. UICC (1997): TNM Klassification Maligner Tumoren, Ed 5. Berlin: Springer.